对于患有球孢子菌病的肿瘤坏死因子α抑制剂接受者，治疗方法存在差异。
Divergence in the approach to tumor necrosis factor α-inhibitor recipients with coccidioidomycosis.
作者信息
Garrett Ashley L, Cha Stephen S, Wack Elizabeth, Blair Janis E
机构信息
Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA.
Department of and Biostatistics, Mayo Clinic, Scottsdale, AZ, USA.
出版信息
Infection. 2017 Aug;45(4):539-543. doi: 10.1007/s15010-017-1029-9. Epub 2017 Jun 2.
BACKGROUND
Tumor necrosis factor α-inhibitors (TNFIs) have been associated with increased risk of certain fungal infections, including coccidioidomycosis. The optimal treatment approach to coccidioidomycosis in TNFI recipients is unknown.
METHODS
We constructed an anonymous, voluntary survey for practicing pulmonary and infectious disease physicians in the state of Arizona regarding approach to TNFI patients with coccidioidomycosis.
RESULTS
There is no current consensus on managing these patients.
CONCLUSIONS
Further research is necessary to determine the optimal approach to TNFI recipients with coccidioidomycosis.
背景
肿瘤坏死因子α抑制剂（TNFIs）与包括球孢子菌病在内的某些真菌感染风险增加有关。TNFIs接受者中球孢子菌病的最佳治疗方法尚不清楚。
方法
我们针对亚利桑那州的执业肺病和传染病医生，就治疗患有球孢子菌病的TNFIs患者的方法构建了一项匿名自愿调查。
结果
目前对于管理这些患者尚无共识。
结论
有必要进行进一步研究以确定TNFIs接受者中球孢子菌病的最佳治疗方法。
Zotero 插件